• About Us
  • Privacy
  • Contact Us

Contact Lens Update

Clinical Insights Based in Current Research

Search Our Site

  • Home
  • Browse Past Issues
  • Resource Library
  • Back to Basics
  • Useful Links
  • About Us
  • Contact Us

Conference Highlights

Examining symptomatic relief and kinetic tear film stability of I-DROP MGD eye drops

November 14th, 2022
Alison Ng  headshotAlison Ng is a clinical scientist at the Centre for Ocular Research & Education, in the School of Optometry & Vision Science at the University of Waterloo.

Download the poster (.pdf) originally shared at the American Optometric Association Annual meeting in 2022.

Examining symptomatic relief and kinetic tear film stability of I-DROP MGD eye drops

Alison Ng, Jaya Dantam, Jill Woods, Blair McEwen, Lyndon Jones

Background: I-DROP MGD is a novel formulation of viscoadaptive hyaluronan, phosphorylcholine and glycerin to support integration, stabilization and enhancement of the tear film lipid layer as well as hydration of the ocular surface. The purpose of this study was to compare the difference in tear film measures after instilling I‑DROP MGD (test) compared with another hyaluronic acid-based lubricant, Thealoz Duo (control), and to examine the subjective relief of dry eye symptoms with I-DROP MGD over 1-week.

Method: This prospective pilot study (n=10) comprised of two parts. Part 1 was a non-dispensing, double-masked study involving contralateral application of test and control drops, followed by a two-hour observation period. Non-invasive tear break-up time (NITBUT), tear meniscus height (TMH) and lipid layer thickness (LLT) were measured out to 2 hours. Part 2 was a dispensing study, where one bottle of I‑DROP MGD was provided to participants to use bilaterally at least once daily for 7 days. After 7 days, subjective ratings (0-100 scale) of comfort, soothing and quality of vision along with OSDI and SPEED scores were collected and compared with participant’s habitual eye drops.

Results: Part 1: NITBUT and TMH were significantly greater with I-DROP MGD (14.2 ± 5.1s and 0.42 ± 0.22mm) compared to Thealoz Duo (10.5 ± 5.7s and 0.29 ± 0.10mm) after 60‑minutes (pNITBUT=0.037) and 5-minutes of instillation (pTMH=0.022) respectively; LLT was significantly thicker with Thealoz Duo (79.5 ± 15.7nm) compared to I-DROP MGD (68.5 ± 13.8nm) after 5‑minutes of instillation (p=0.005). Part 2: Subjective ratings for comfort and soothing were significantly greater with I-DROP MGD (81.6 ± 5.7 and 86.8 ± 8.1) compared to habitual eye drops (73.3 ± 13.7 and 75.3 ± 19.8), p=0.027 and p=0.010 respectively. No significant differences were observed for quality of vision. OSDI and SPEED scores were significantly lower following use of I‑DROP MGD (33.2 ± 11.7 and 11.1 ± 3.6) when compared to habitual drops (45.2 ± 14.7 and 14.9 ± 2.7), p=0.017 and p=0.006 respectively.

Conclusion: When used for 7 days, I-DROP MGD resulted in clinically relevant reductions in dry eye symptoms, measured with OSDI.

Related Articles

  • November 14, 2022

    Examining symptomatic relief and kinetic tear film stability of I-DROP MGD eye drops

  • November 14, 2022

    Prescribing Lubricating Eye Drops for Common Ocular Conditions

  • November 14, 2022

    Practitioner Reference: Artificial Tear Ingredient Fact Sheet

  • November 14, 2022

    Article Review: Rheological behavior of commercial artificial tear solutions

Issues

  • Multifocal Contact Lenses
  • Artificial Tears: An Update
  • Myopia: New Evidence and Best Practices
  • Neuropathic Pain
  • Specialty Rigid Lenses
  • Contact lens compliance
  • Pandemic update
  • Digital Devices and Dry Eye: A Growing Issue
  • The long and short of axial length
  • Using BCLA CLEAR with your patients
  • Helping your patients through allergy season
  • Getting the measure of meibomian glands
  • 2020: An extraordinary year
  • Scleral lens update
  • A dose of myopia
  • New news since TFOS DEWS II
  • COVID-19 Special Edition
  • Material considerations
  • Putting dry eye theory into practice
  • Getting started with Ortho-K
  • Infiltrates – an update
  • Staining
  • Myopia matters: Summarising the IMI reports
  • Lids and contact lenses
  • Myths
  • Revisiting patient compliance
  • Contact Lenses & Kids
  • Interprofessional Collaboration
  • Digital eye strain
  • New Dry Eye Technology
  • Update on Presbyopia
  • Taking stock of dry eye disease: DEWS II
  • Scleral Lenses
  • Pain and Sensation
  • Lab measurements in clinical practice
  • Control of pediatric myopia
  • Nutrition
  • Rethinking contact lens deposits
  • Extended wear
  • Daily Disposables
  • Eyelash Mites (Demodex)
  • Outsmarting bacteria with new technology
  • Youth and contact lenses
  • Sports Vision
  • Ocular effects of UV radiation from the sun
  • Eyelid Conditions
  • Makeup: Impact on ocular health
  • Myopia Control – Update 2014
  • The Growing Prevalence of Myopia
  • Cosmetic contact lenses
  • Contact lens discomfort – The essentials
  • Technology and contact lens research
  • It's A Question of Comfort
  • Contact lens materials
  • Let's talk about SICS
  • Conjunctival Controversies
  • Kids & Contact Lenses
  • One-day silicone hydrogel lenses
  • Solutions
  • Spotlight on Scleral lenses
  • Drug delivery via contact lenses
  • Ocular allergies
  • Reducing lens case contamination
  • Dry eye and meibomium gland dysfunction
  • Myopia Control
  • Presbyopia
  • Compliance and non-compliance
  • Lens care
  • Celebrating 50 years of contact lenses

Looking for another article?

Alcon coopervision Johnson&Johnson Vision Care

Newsletter Sign-Up

Sign-up for and start receiving our newsletter.

Site Map

  • Home
  • Browse Past Issues
    • Editorial
    • Feature Article
    • Clinical Insight
    • Conference Highlights
  • Resource Library
  • Back to Basics
  • Useful Links
  • About Us
  • Contact Us
© 2023 Contact Lens Update